HepaSphere载药微球栓塞治疗原发性肝癌的近期疗效及安全性

Short-term Efficacy and Safety of HepaSphere Drug-loaded Microsphere Embolization on Primary Hepatocellular Carcinoma

目的观察HepaSphere载药栓塞微球的肝动脉化疗栓塞术在原发性肝细胞癌治疗中的近期临床疗效及其安全性。方法回顾性收集分析2015年6月-2017年7月使用DEB-TACE治疗的原发性肝癌患者共58例。通过CT或MR比较患者近期肿瘤局部反应,通过相关检查结果及临床症状观察对比患者术后并发症、肝功能改变等。结果 TACE术后肝功能表现为一过性改变;术后并发症均在可接受范围内,对症支持处理后均可缓解;术后平均住院时间为1.72天。根据mRECIST标准,1月客观缓解率(CR+PR)为81.0%,疾病控制率(CR+PR+SD)为96.6%;3月客观缓解率(CR+PR)为75.9%,疾病控制率(CR+PR+SD)为93.1%;6月客观缓解率(CR+PR)为65.5%,疾病控制率(CR+PR+SD)为87.9%;一年生存率为93.1%。结论使用DEB-TACE治疗不可切除肝癌的近期临床疗效及安全性均较好。

Objective To evaluate the short-term clinical efficacy and safety of transcatheter arterial chemoembolization using HepaSphere microsphere in the treatment of primary hepatocellular carcinoma with HepaSphere microspheres. Methods We retrospectively analyzed 58 patients with hepatocellular carcinoma treated with HepaSphere microspheres (loaded with pirarubicin) from June 2015 to July 2017. We compared the local tumor response by CT or MR. The postoperative complications and liver function changes were compared by relevant examination results and clinical symptoms. Results The liver function showed a transient change after TACE. Postoperative complications were acceptable and could be alleviated after symptomatic support. The average postoperative hospital stay was 1.72 days. According to the mRECIST criteria, the objective response rates (CR+PR) were 81.0%, 75.9%, 65.5%, and the disease control rates (CR+PR+SD) were 96.6%, 93.1%, 87.9% at 1, 3, 6 months after treatment. The one-year survival rate was 93.1%. Conclusion The short-term clinical efficacy and safety of transarterial chemoembolisation using HepaSphere microspheres on unresectable hepatocellular carcinoma are acceptable.